Investing.comMar 5, 2:42 PM ET▲ Positive
Arbutus receives settlement payment from Moderna, providing financial benefit and resolution of long-running legal dispute.
Arbutus Biopharma news
$4.69−3.50%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Arbutus Biopharma
No recent articles focused on Arbutus Biopharma.
Also mentions ABUS
Articles that tag ABUS but are mainly about other companies.
BenzingaMar 4, 8:14 AM ETNeutral
As a co-plaintiff in the settlement, the company receives payment but limited details provided about the financial impact or terms specific to Arbutus. Stock declined 6.61% despite settlement, suggesting market may view the settlement terms unfavorably.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology